Catalyst
Slingshot members are tracking this event:
FDA Approves Celgene's (CELG) REVLIMID in Treating Multiple Myeloma (MM) Following Autologous Stem Cell Transplant (ASCT)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 22, 2017
Occurred Source:
http://www.businesswire.com/news/home/20170222006533/en/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Revlimid, Multiple Myeloma, Autologous Stem Cell Transplant
